Plandai Biotechnology Inc (OTCMKTS:PLPL) stock has been stuck in a trading range of since the start of this month. After reporting two strong sessions earlier this week, the stock registered a red session on Tuesday and declined over 3% to close at $0.125. The company recently stated that it extended its three-year contract with USN. The group well understands the many advantages of phyto-availability and therefore, has decided to use the Phytofare® catechin complex in its new products to be sold in new target regions. Phytofare® is believed to be a magical ingredient that delivers active components to the blood stream.
The management of Plandai said that that they are delighted with the extended agreement as USN begins the use of Phytofare in its products South Africa and Europe and markets. This extended deal is encouraging for company in terms of revenue and reputation in the market.
Cannabis Science Inc (OTCMKTS:CBIS) Engages New Chief Medical Officer
Cannabis Science Inc (OTCMKTS:CBIS) stated that the renowned epidemiologist, scholar and public health physician Allen A. Herman, M.B., Ch.B., Ph.D. will serve as the new Chief Medical Officer of company. Dr. Herman is already associated with Cannabis as a member of its Scientific Advisory Board.
Cannabis Science reported that Dr. Herman served as a program director and project officer at the reputed group, NIH. For his achievements in field of child and maternal health, he was recognized with the Award of Merit. Dr. Herman worked on the unique platform for infant mortality reduction in the U.S. and also served as the co-director of the various projects handled by the CDC and NIH in conjunction.
Metabolix, Inc. (NASDAQ:MBLX) Takes A Hit
In last trading session, the share price of Metabolix, Inc. (NASDAQ:MBLX) declined more than 10% to close the day at $1.76. The company recently established a ‘Yield10 Bioscience’ team to extend the innovation measures in segment of crop science.
